Wei Fang HENGCCAI Digital photo Material Co.,LTD organized its core sales team to participate in the AI Hawk Training Conference, focusing on cultivating AI-driven sales thinking and global market expansion capabilities. The training carried out targeted sales skill polishing for the company's four core products: medical thermal dry image film, inkjet film, medcial laser film and x-ray film, helping sales personnel master differentiated promotion strategies for different overseas markets. The company will take this training as a starting point to further expand the global layout of its imaging materials products.

This press release focuses on high-performance Medical X-Ray Film, a core essential medium for modern medical imaging diagnosis and clinical examination. With continuous technological upgrades, optimized production formulas and advanced coating processes have greatly enhanced the imaging clarity, chemical stability and storage durability of Medical X-Ray Film. Fully compliant with international medical standards, Medical X-Ray Film delivers distortion-free, high-precision imaging details, supporting accurate diagnosis for orthopedics, pulmonology, routine physical examinations and emergency medical scenarios. Featuring eco-friendly, non-toxic materials and reliable safety performance, the upgraded Medical X-Ray Film avoids environmental pollution and human body irritation during use and disposal. Driven by the growing global medical examination demand and aging population, the market demand for standardized Medical X-Ray Film keeps rising. Widely adopted by various medical institutions, high-quality Medical X-Ray Film effectively improves clinical diagnosis efficiency, reduces medical resource waste, and boosts remote medical resource sharing. The integration of Medical X-Ray Film with digital medical technology will further lead the standardized and intelligent development of the global medical imaging industry.

At Cairo Egypt Health Expo, Weifang Hengcai unveiled climate-engineered medical thermal dry image film, inkjet film, medical laser film, x-ray film samples to Egyptian radiologists, veterinarians and dental surgeons. Live demos, Arabic-English brochures and cost-saving spreadsheets drove 96 % satisfaction ratings and forty-container follow-up orders for medical thermal dry image film, inkjet film, medical laser film, x-ray film within fourteen days. Expanded distributor agreements now cover Sinai and Red Sea regions, with dedicated Cairo warehousing and November training summits securing long-term growth for medical thermal dry image film, inkjet film, medical laser film, x-ray film across Egypt.

At São Paulo Hospitalar, regional representative Anders led Weifang Hengcai's push for medical thermal dry image film, inkjet film, medical laser film, x-ray film through 47 live demos, 17 distributor meetings and 136 new contacts. Anders' rooftop reception secured 23 purchase intentions totaling 156 tonnes of medical thermal dry image film, inkjet film, medical laser film, x-ray film, projecting 41 % Brazil revenue growth. Anders also identified veterinary and industrial cross-selling channels for medical thermal dry image film, inkjet film, medical laser film, x-ray film, earning top regional contributor recognition and planning replication in Mexico City and Buenos Aires.

At Shanghai CMEF, Weifang Hengcai welcomed buyers from the India-Pakistan market, Southeast Asia market, Africa market, South America market and North America market, demonstrating medical thermal dry image film, inkjet film, medical laser film, x-ray film through live chest prints, colour Doppler overlays and tropical-condition simulations. Delegates carried sample rolls of medical thermal dry image film, inkjet film, medical laser film, x-ray film home, returned 94 % excellent ratings and drove a 73 % reorder rate within six weeks, prompting 15 % production-line acceleration and dedicated warehouse bays for medical thermal dry image film, inkjet film, medical laser film, x-ray film across all five continents.

Wei Fang HENGCCAI Digital Photo Material Co., LTD will participate in CMEF 2024, showcasing medical thermal dry image film, inkjet film, medical laser film, and x-ray film. The company aims to engage clients from Asia, Africa, South America, and Europe, offering customized, eco-friendly solutions tailored to regional needs. Through live demos, workshops, and R&D insights, it will highlight product innovations like anti-static layers and biodegradable packaging. The event serves as a platform to strengthen partnerships and drive sustainable growth in global healthcare.

Wei Fang HENGCCAI Digital Photo Material Co., LTD shone at the 2026 Dubai Arab Health Exhibition, focusing on the Middle East, Indian, and African markets. The company showcased products including medical thermal dry films, inkjet films, medical laser films, and X-ray films. Its upgraded medical thermal dry films earned praise for high efficiency and durability, while the eco-friendly properties of its inkjet films aligned with the needs of GCC countries. During the exhibition, the company secured partnerships with multiple countries, significantly boosting brand recognition and garnering extensive media coverage. Moving forward, the company will establish regional warehouses, launch certification programs, and increase investment in AI-driven quality inspection, aiming to become a leader in medical imaging materials for emerging markets.

January 2026 sales vaulted 30 % above target as the medical-film team shipped 220 t domestically and 48 containers overseas of medical thermal dry image film, inkjet film, medical laser film, x-ray film. New customers rose 27 %, cross-selling bundles lifted average order value 18 % and two-shift production maintained 99.2 % quality pass rates on medical thermal dry image film, inkjet film, medical laser film, x-ray film. The result sets a double-digit growth trajectory for medical thermal dry image film, inkjet film, medical laser film, x-ray film through Q1 roadshows in Dubai, Mumbai and São Paulo.

A recent breakthrough in medical research has sparked widespread attention. Scientists have developed a new drug that shows great promise in treating a previously incurable disease. Early clinical trials demonstrate significant improvement in patients' conditions with minimal side effects. This innovation not only offers hope to millions suffering from the illness but also represents a major leap forward in medical science. Researchers are now planning larger-scale trials to confirm its efficacy and safety, aiming to bring this life-changing treatment to the market as soon as possible, potentially revolutionizing healthcare for countless individuals worldwide.